These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 37158346)

  • 1. New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 1: Ruxolitinib.
    Mancuso-Stewart E; DiRuggiero M; DiRuggiero D; Zirwas M
    Skinmed; 2023; 21(2):93-98. PubMed ID: 37158346
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 3: Roflumilast.
    DiRuggiero M; Mancuso-Stewart E; DiRuggiero D; Zirwas M
    Skinmed; 2023; 21(4):264-268. PubMed ID: 37771017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. New Non-Steroidal Topical Therapies for Inflammatory Dermatoses-Part 2: Tapinarof.
    DiRuggiero M; Mancuso-Stewart E; DiRuggiero D; Zirwas M
    Skinmed; 2023; 21(3):177-181. PubMed ID: 37634099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of Safety, Efficacy, and Patient Counseling for Ruxolitinib in Treating Atopic Dermatitis.
    Mancuso-Stewart E; Rodger J; Zirwas M
    Skinmed; 2023; 21(1):40-43. PubMed ID: 36987827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-World Use of Ruxolitinib Cream: Safety Analysis at 1 Year.
    Hu W; Thornton M; Livingston RA
    Am J Clin Dermatol; 2024 Mar; 25(2):327-332. PubMed ID: 38243107
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Off-label Studies on the Use of Ruxolitinib in Dermatology.
    Tegtmeyer K; Ravi M; Zhao J; Maloney NJ; Lio PA
    Dermatitis; 2021 May-Jun 01; 32(3):164-172. PubMed ID: 33443378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tapinarof, a Novel, First-in-Class, Topical Therapeutic Aryl Hydrocarbon Receptor Agonist for the Management of Psoriasis.
    Bobonich M; Gorelick J; Aldredge L; Bruno MJ; DiRuggiero D; Martin G; Tallman AM; Gold LS
    J Drugs Dermatol; 2023 Aug; 22(8):779-784. PubMed ID: 37556512
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ruxolitinib Cream 1.5%: A Review in Mild to Moderate Atopic Dermatitis.
    Hoy SM
    Am J Clin Dermatol; 2023 Jan; 24(1):143-151. PubMed ID: 36538235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Emerging role of topical Janus kinase inhibitors in dermatological disorders: a review.
    Dogra S; Sharma A; Mehta H; Sarkar R
    Clin Exp Dermatol; 2023 Sep; 48(10):1102-1112. PubMed ID: 37235767
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Utilization of Topical Ruxolitinib in Dermatology: A Review.
    Kashetsky N; Turchin I
    Skin Therapy Lett; 2023 May; 28(3):8-13. PubMed ID: 37339609
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of ruxolitinib cream 1.5% as an at-home therapy for repigmentation in non-segmental vitiligo.
    Agner ML; Parraga SP; Arkhipenko ZM; Pichardo RO; McMichael AJ; Feldman SR
    Expert Rev Clin Immunol; 2024 Jul; 20(7):695-702. PubMed ID: 38879876
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tapinarof for psoriasis and atopic dermatitis: 15 years of clinical research.
    Bissonnette R; Saint-Cyr Proulx E; Jack C; Maari C
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):1168-1174. PubMed ID: 36708084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Topical Janus kinase inhibitors: A review of applications in dermatology.
    Hosking AM; Juhasz M; Mesinkovska NA
    J Am Acad Dermatol; 2018 Sep; 79(3):535-544. PubMed ID: 29673776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. JAK-inhibitors in dermatology: current evidence and future applications.
    Ciechanowicz P; Rakowska A; Sikora M; Rudnicka L
    J Dermatolog Treat; 2019 Nov; 30(7):648-658. PubMed ID: 30433838
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tapinarof Cream 1%: First Approval.
    Keam SJ
    Drugs; 2022 Jul; 82(11):1221-1228. PubMed ID: 35939180
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Clinical Applications of Topical Ruxolitinib: A Case Series.
    Zundell MP; Al-Dehneem R; Song T; Yousif J; Gottlieb AB
    J Drugs Dermatol; 2024 Mar; 23(3):188-190. PubMed ID: 38443119
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Janus Kinase Inhibitors in Dermatology: Part 2: Applications in Psoriasis, Atopic Dermatitis, and Other Dermatoses.
    Garcia-Melendo C; Cubiró X; Puig L
    Actas Dermosifiliogr (Engl Ed); 2021; 112(7):586-600. PubMed ID: 34030992
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Janus kinase (JAK) inhibitors for the treatment of skin and hair disorders: a review of literature.
    Samadi A; Ahmad Nasrollahi S; Hashemi A; Nassiri Kashani M; Firooz A
    J Dermatolog Treat; 2017 Sep; 28(6):476-483. PubMed ID: 28024126
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Off-label studies on ruxolitinib in dermatology: a review.
    Wu J; Smogorzewski J
    J Dermatolog Treat; 2022 Mar; 33(2):606-612. PubMed ID: 32515635
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluating topical JAK inhibitors as a treatment option for atopic dermatitis.
    Fardos MI; Singh R; Perche PO; Kelly KA; Feldman SR
    Expert Rev Clin Immunol; 2022 Mar; 18(3):221-231. PubMed ID: 34637367
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.